“Our advantage is our multi-faceted experiences in the biopharmaceutical industry”

“...partnership sourcing and contract negotiations...”


About Us

Waverly BioConsulting is dedicated to unlocking the value in every biopharmaceutical company client.

Our advantage is our multi-faceted experiences in the biopharmaceutical industry—as a scientist, a Wall Street analyst, and in commercial, operational, and business development positions at both large and small pharma companies.

As the Founding Partner of Waverly BioConsulting, Dr. Deborah Knobelman brings over 15 years of experience from academia, Wall Street, and the biopharmaceutical industry. Most recently, Dr. Knobelman was the Chief Business Officer of Ampio Pharmaceuticals, a small cap public biotech company. In her capacity as Chief Business Officer, she headed the business development group, including partnership sourcing and contract negotiations for out licensing, collaborations, and supply agreements related to the company's pipeline products. Her involvement lead directly to multiple international product partnerships. Dr. Knobelman was also highly involved in market research, corporate financings, investor roadshows, budgeting, and valuation analyses. She was a key participant in corporate strategy and operational decision making. She also had involvement in regulatory strategy and execution.

Dr. Knobelman joined Ampio from Pfizer, where she held a variety of positions, most recently Director of Strategy and Analytics for Pfizer's Primary Care product portfolio. While at Pfizer, she focused on optimizing commercial strategies for the company's Primary Care portfolio. Specifically, Dr. Knobelman was involved in sales force deployment reconfigurations, resource allocation, annual operational planning, and budgeting. Interactions with marketing, finance, sales, and business development were all integral parts of the position.

Prior to Pfizer, Dr. Knobelman spent 7 years on Wall Street as an Equity Research Analyst, following the Specialty Pharmaceuticals sector at several investment banks, including Piper Jaffray and JPMorgan. In 2005 she was named to Institutional Investor magazine's list of "Next Generation" analysts for her work following Specialty Pharma stocks.

Dr. Knobelman earned a PhD in Pharmacology from the University of Pennsylvania, where she studied the role of serotonin receptors in the brain and was granted a National Research Service Award from the National Institutes of Mental Health for her work. She has authored several papers published in leading scientific journals. Dr. Knobelman received an AB with Distinction in Chemistry from Duke University.